Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Status:
Completed
Trial end date:
2016-01-07
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of icotinib in treating advanced
carcinoma of the gastroesophageal junction and esophagus with EGFR overexpression (IHC 3+) or
positive FISH, the primary endpoint is objective response rates.